This study is testing resmetirom, a medication already on the market, to see if it can reduce liver fat in people living with HIV who also have MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease). Researchers want to find out if resmetirom is safe and effective for this group, as they weren't included in earlier studies. You might be eligible if you are an adult (18 or older) with documented HIV and MASLD. Participants will receive either resmetirom or a placebo (an inactive pill that looks the same) daily for 24 weeks. The main goal is to see if resmetirom decreases the amount of fat in the liver after 24 weeks.

Study design

This is an interventional study comparing resmetirom to a placebo in approximately 120 participants. It is testing a drug already on the market for a new population.

What's involved

You will complete 3 screening visits, take resmetirom or placebo daily for 24 weeks, and have 2 MRI scans to measure liver fat.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome is measured at 24 weeks, which is the end of treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.